Red Light Holland Secures Second United States Controlled Substances Import Permit for the Company's Psilocybin Through FDA-Compliant, DEA-Registered Partner Irvine Labs

• Red Light Holland granted Second DEA Import Permit through Irvine Labs for expanded psilocybin research program
• This United States Controlled Substances Permit, authorizes a significantly larger shipment of psilocybin truffles, from Red Light Holland's Netherlands facility, for continued R&D

Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms, mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal recreational market within the Netherlands, in compliance with all applicable laws, announced today that its research and development partner, Irvine Labs Inc., California, USA, has received a second United States Controlled Substances import permit. This latest import permit authorizes a significantly larger shipment of psilocybin truffles for continued research and development activities by their FDA-Compliant, DEA-Registered Lab partner.

The Drug Enforcement Administration issued permit authorizes the import equivalent to 5 kg of psilocybin truffles from Red Light Holland's Netherlands facility. This second import permit represents substantial progress following the successful completion of initial testing and validation work announced in September 2025, which confirmed psilocybin potency and process validation through an official Certificate of Analysis (COA). The increased quantity authorized under this USA controlled substances permit will enable Irvine Labs to advance proprietary dehydration and packaging processes designed to extend shelf life while maintaining product integrity, and to further develop standardized psilocybin products for potential medical grade manufacturing applications.

Red Light Holland and Irvine Labs continue to work collaboratively toward developing processes for the commercial manufacture of microdosing capsules derived from naturally occurring psilocybin truffles, aimed at emerging therapeutic markets, government-funded pilot programs, and clinical trials.

"This second DEA permit marks a significant milestone in our partnership with Irvine Labs and validates the progress we've made in our research and development efforts," said Todd Shapiro, Chief Executive Officer & Director of Red Light Holland. "The increased quantity authorized demonstrates growing confidence in our ability to provide high-quality, naturally derived psilocybin materials suitable for potential medical grade applications, while maintaining full regulatory compliance."